Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results From a Phase III Clinical Trial and Long-term Extension.

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results From a Phase III Clinical Trial and Long-term Extension. Acta Derm Venereol. 2017 Sep 20;: Authors: Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Burge R, Lin CY, Yosipovitch G Abstract Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). We assessed the long-term (through 60 weeks) effect of ixekizumab maintenance therapy (80-mg ixekizumab every 4 weeks [IXEQ4W]) on itch severity, using the Itch Numeric Rating Scale, in psoriasis patients who received ixekizumab, placebo, or etanercept for 12 weeks in the Phase III UNCOVER-3 trial. After 12 weeks, patients either continued or switched to IXEQ4W. Mean improvements in itch severity achieved with 12 weeks of ixekizumab (â€"4.7 to â€"5.1) were maintained through 60 weeks with IXEQ4W (â€"4.9 to â€"5.0). Patients who initially received placebo or etanercept experienced rapid itch severity improvements after switching to ixekizumab at Week 12 (Week 12, placebo: â€"0.6; etanercept: â€"3.8; Week 60, placebo/IXEQ4W: â€"4.9; etanercept/IXEQ4W: â€"4.7). Ixekizumab maintenance therapy sustained improvements in itch severity through 60 weeks. PMID: 28929168 [PubMed - as supplied by publisher]
Source: Acta Dermato-Venereologica - Category: Dermatology Authors: Tags: Acta Derm Venereol Source Type: research